Grafa News and Videos — Page 17

Jaguar Health (NASDAQ:JAGX) reported second-quarter 2026 net revenue of $1.2 million, down 59% year over year, following the U.S. commercialization transfer of Mytesi and Canalevia-CA1 to Future Pak affiliate Woodward Specialty.

BILL Holdings (NYSE:BILL) reported fiscal 2026 total revenue of $1.7 billion, up 13% year over year, while core revenue increased 16% to $1.5 billion.

Motorola Solutions (NYSE:MSI) announced that its board of directors approved a regular quarterly cash dividend of $1.21 per share.

Femasys (NASDAQ:FEMY) announced that the U.S. FDA approved its modular premarket approval submission approach for FemBloc, the company’s investigational non-surgical permanent birth control technology.

Kiora Pharmaceuticals (NASDAQ:KPRX) licensed South Korean development and commercialization rights for its retinal therapy KIO-301 in ophthalmic indications to Chong Kun Dang Pharmaceutical (CKD).

Blockchain analytics firm Arkham has identified that the wallet pension-usdt.eth is holding an US$85 million short position on Ethereum (CRYPTO:ETH), opened at an average entry price of approximately US$1,700 and now sitting at an unrealised loss of approximately US$9.8 million as ETH approaches US$1,900.

Biodexa (NASDAQ:BDRX) announced that 87 of a planned 168 subjects have been enrolled in its registrational Phase 3 Serenta trial evaluating eRapa in Familial Adenomatous Polyposis (FAP).

Cosmos Health (NASDAQ:COSM) reported record second-quarter 2026 revenue of $18.99 million, up 28.8% year over year, with first-half revenue increasing 29.7% to $36.91 million.

Top Wealth Group Holding (NASDAQ:TWG) reported unaudited first-half 2026 revenue of $6.1 million, up 48% from $4.2 million a year earlier, driven mainly by expansion of its premium wine distribution business.

Teva Pharmaceuticals (NYSE:TEVA) announced that the U.S. FDA accepted its New Drug Application for ecopipam (EBS-101) and granted Priority Review for pediatric Tourette syndrome.